Our History



March 27, 2007

The ophthalmic pharmaceutical companies Acuity Pharmaceuticals and the Froptix Corporation merge with eXegenics Inc. to form OPKO Health.

November 29, 2007

OPKO completes the acquisition of Ophthalmic Technologies, Inc.


October 02, 2009

OPKO acquires the Chilean pharmaceutical distributor Pharma Genexx S.A., which marks the beginning of OPKO's Latin American presence.


February 18, 2010

OPKO acquires Mexican drug manufacturer and distributor Pharmacos Exakta, S.A. de C.V

December 14, 2010

OPKO and TESARO, Inc. sign an exclusive license agreement for the development and marketing of the oncology support drug, Rolapitant®


October 13, 2011

OPKO acquires microfluidics based diagnostic test system developer, Claros Diagnostics.


January 23, 2012

OPKO acquires kallikrein based prostate cancer diagnosis test from Arctic Partners Ab Oy. This test would become the basis for OPKO's 4Kscore® prostate cancer risk assessment blood test.

August 03, 2012

OPKO acquires Spanish pharmaceutical, nutraceutical and veterinary product company, Farmadiet Group Holding, S.L.


January 08, 2013

OPKO acquires Cytochroma Inc. and their lead nephrology products, Rayaldee® and Alpharen®.

August 29, 2013

OPKO acquires PROLOR Biotech, with platform technologies to extend the biological half-life of therapeutic proteins and peptides. This technology is used in OPKO's clinical stage hGH-CTP, for the treatment of growth hormone deficiency, and in Factor VIIa-CTP for the treatment of hemophilia A & B.


March 31, 2014

OPKO Launches the 4Kscore® test in the United States (U.S). The 4Kscore® test is performed after an elevated prostate-specific antigen (PSA) test result to risk stratify the detection of aggressive prostate cancer.

May 19, 2014

OPKO presents data demonstrating that the 4Kscore® is an accurate, sensitive, and personalized predictor of high-grade prostate cancer at the American Urological Association Plenary Session.

September 15, 2014

OPKO Launches the 4Kscore® test in Europe.

December 15, 2014

OPKO and Pfizer, Inc. enter into a strategic partnership for the development and commercialization of OPKO’s long-acting human growth hormone, hGH-CTP.


May 05, 2015

OPKO acquires EirGen Pharmaceuticals, Ireland. EirGen specializes in the development and manufacturing of high potency pharmaceutical products.

August 20, 2015

OPKO acquires the full service clinical laboratory, BioReference Laboratories, Inc.

December 09, 2015

OPKO subsidiary GeneDx demonstrates that whole exome sequencing can provide a definitive diagnosis for patients with rare and complex genetic conditions.


May 09, 2016

OPKO and Vifor Fresenius Medical Care Renal Pharma entered into a collaboration and license agreement for the development and commercialization of Rayaldee® in Europe, Canada, Mexico, Australia, South Korea and other international markets for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) and vitamin D insufficiency.

June 21, 2016

The U.S Food and Drug Administration (FDA) approves a New Drug Application (NDA) for Rayaldee® (calcifediol) extended release capsules for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency, defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.

August 31, 2016

OPKO acquires the Canadian biopharmaceutical company Transitions Therapeutics and their products in late-stage clinical development.

October 27, 2016

OPKO enters into the animal health market with the launch of its line of U.S veterinary pharmaceuticals and nutraceuticals.


October 12, 2017

OPKO enters into an exclusive agreement with Japan Tobacco Inc. (JT) for the development and commercialization in Japan of Rayaldee® in Japan.


July 16, 2018

OPKO's strategic partner Vifor Fresenius receives marketing approval for Rayaldee® in Canada.


February 01, 2019

OPKO receives FDA approval for the point-of-care Sangia PSA Test with the Claros® 1 Analyzer.